A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice1
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) pathophysiology is poorly understood, due partly to lack of PCOS animal models fully recapitulating this complex disorder. Recently, a PCOS rat model using letrozole (LET), a nonsteroidal aromatase inhibitor, mimicked multiple PCOS phenotypes, including metabolic features absent in other models. Given the advantages of using genetic and transgenic mouse models, we investigated whether LET produces a similar PCOS phenotype in mice. Pubertal female C57BL/6N mice were treated for 5 wk with LET, which resulted in increased serum testosterone and normal diestrus levels of estradiol, similar to the hyperandrogenemia and follicular phase estrogen levels of PCOS women. As in PCOS, ovaries from LET mice were larger, polycystic, and lacked corpora lutea versus controls. Most LET females were acyclic, and all were infertile. LET females displayed elevated serum LH levels and higher Lhb mRNA in the pituitary. In contrast, serum FSH and Fshb were significantly reduced in LET females, demonstrating differential effects on gonadotropins, as in PCOS. Within the ovary, LET females had higher Cyp17, Cyp19, and Fsh receptor mRNA expression. In the hypothalamus, LET females had higher kisspeptin receptor mRNA expression but lower progesterone receptor mRNA levels. LET females also gained more weight than controls, had increased abdominal adiposity and adipocyte size, elevated adipose inflammatory mRNA levels, and impaired glucose tolerance, mirroring the metabolic phenotype in PCOS women. This is the first report of a LET paradigm in mice that recapitulates both reproductive and metabolic PCOS phenotypes and will be useful to genetically probe the PCOS condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Vogel, C., & Marcotte, E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3185 · Cited by 4,195 · cited 1×
“Because mRNA levels do not always represent protein levels [54, 55], future studies using fixed tissues will need to determine if the alterations in mRNA expression observed in our study reflect similar alterations in protein levels.”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132 · cited 1×
“Along with hyperandrogenemia, disruptions in the neuroendocrine reproductive axis contribute to dysfunctional ovarian maturation and diminished fertility [1, 3, 4, 6].”
BackgroundFauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 1×
“It has been suggested that the absence of significant metabolic dysfunction or obesity in PNA mice signifies it as a lean PCOS model [73] and could be useful for representing the condition in some PCOS women who lack metabolic impairments [74].”
BackgroundComparing protein abundance and mRNA expression levels on a genomic scale
Greenbaum, D. (2003) · Genome biology · doi:10.1186/gb-2003-4-9-117 · Cited by 1,692 · cited 1×
“Because mRNA levels do not always represent protein levels [54, 55], future studies using fixed tissues will need to determine if the alterations in mRNA expression observed in our study reflect similar alterations in protein levels.”
BackgroundPolycystic ovary syndrome: etiology, pathogenesis and diagnosis
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.217 · Cited by 1,488 · cited 4×
“Inadequate FSH levels in PCOS women contribute to impaired follicular development, while elevated LH levels augment ovarian androgen production [6].”
BackgroundInfluentialMoran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108 · cited 2×
“Along with the reproductive phenotype, many women with PCOS have metabolic abnormalities, including peripheral insulin resistance, hyperinsulinemia, and abdominal adiposity that increase their risk of developing type 2 diabetes and cardiovascular disease [9, 65, 66].”
BackgroundWild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010
Wild, S., Pierpoint, T., McKeigue, P., & Jacobs, H. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01000.x · Cited by 970 · cited 1×
“Along with the reproductive phenotype, many women with PCOS have metabolic abnormalities, including peripheral insulin resistance, hyperinsulinemia, and abdominal adiposity that increase their risk of developing type 2 diabetes and cardiovascular disease [9, 65, 66].”
BackgroundStepto, N. K., Cassar, S., Joham, A. E., Hutchison, S. K., Harrison, C. L., Goldstein, R. F., & Teede, H. J. (2013) · Human Reproduction · doi:10.1093/humrep/des463 · Cited by 747
Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome
Legro, R. S., Driscoll, D., Strauss, J. F., Fox, J., & Dunaif, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14956 · Cited by 699
PLYMATE, S. R., MATEJ, L. A., JONES, R. E., & FRIEDL, K. E. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-460 · Cited by 693
Androgen and follicle stimulating hormone interactions in primate ovarian follicle development
Weil, S., Vendola, K., Zhou, J., & Bondy, C. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5929 · Cited by 592 · cited 8×
“It is possible that E2 levels are initially decreased by LET but eventually return to normal levels as a long-term consequence of the dramatic increases observed in Cyp19 gene expression (aromatase) and T synthesis (the primary substrate for E2).”
BackgroundInfluentialNelson, V. L., Legro, R. S., Strauss, J. F., & McAllister, J. M. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.6.0311 · Cited by 556
Obesity and androgens: facts and perspectives
Pasquali, R. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.10.054 · Cited by 469 · cited 1×
“Furthermore, as occurs in rodents on high-fat diet [40], obesity in women promotes increased androgen secretion [41], which exacerbates the PCOS pathology in cases in which it is accompanied by metabolic dysfunction.”
BackgroundCarmina, E., Rosato, F., Jannì, A., Rizzo, M., & Longo, R. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1457 · Cited by 420
The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome
Blank, S. K., McCartney, C. R., & Marshall, J. C. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml017 · Cited by 301 · cited 2×
“PCOS is a complex disorder encompassing multiple phenotypic parameters, including neuroendocrine and ovarian impairments, and a high prevalence of metabolic perturbation, such as obesity and glucose intolerance [8–10].”
BackgroundPastor, C. L., Griffin-Korf, M. L., Aloi, J. A., Evans, W. S., & Marshall, J. C. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4604 · Cited by 263
Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome
Moghetti, P., Tosi, F., Bonin, C., Di Sarra, D., Fiers, T., Kaufman, J.-M., Giagulli, V. A., Signori, C., Zambotti, F., Dall'Alda, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3908 · Cited by 262 · cited 1×
“Metabolic dysfunction has been shown to occur predominantly in PCOS women with hyperandrogenism and ovulatory dysfunction, regardless of their body mass index [67, 68].”
BackgroundBarber, T. M., Wass, J. A. H., McCarthy, M. I., & Franks, S. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02764.x · Cited by 254 · cited 1×
“Metabolic dysfunction has been shown to occur predominantly in PCOS women with hyperandrogenism and ovulatory dysfunction, regardless of their body mass index [67, 68].”
BackgroundIto, Y., Fisher, C. R., Conte, F. A., Grumbach, M. M., & Simpson, E. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11673 · Cited by 218 · cited 1×
“This model is based on the finding of lower estrogen/androgen ratios in follicular fluid of PCOS women, suggesting low aromatase activity [28], and the fact that genetic variants of the aromatase gene (CYP19), which converts androgens to estrogen, are associated with the development of PCOS and hyperandrogenism in wom…”
MethodPrenatal androgen exposure programs metabolic dysfunction in female mice
Roland, A. V., Nunemaker, C. S., Keller, S. R., & Moenter, S. M. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0217 · Cited by 184
Abbott, D. H., Tarantal, A. F., & Dumesic, D. A. (2009) · American Journal of Primatology · doi:10.1002/ajp.20679 · Cited by 177 · cited 1×
“Prenatally androgenized rhesus monkey and sheep display many of the reproductive and metabolic phenotypes associated with PCOS [15, 16], but ethical and economic considerations limit the utility of nonhuman primate and large domestic animal models as does the current inability to genetically and transgenically manipul…”
BackgroundNeuroendocrine dysfunction in polycystic ovary syndrome
Burt Solorzano, C. M., Beller, J. P., Abshire, M. Y., Collins, J. S., McCartney, C. R., & Marshall, J. C. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.007 · Cited by 173 · cited 1×
“In addition to hyperandrogenemia, persistently rapid GnRH pulsatility is a neuroendocrine hallmark of PCOS [42], and this favors pituitary synthesis and secretion of LH over FSH and higher LH-to-FSH ratios.”
BackgroundFoecking, E. M., Szabo, M., Schwartz, N. B., & Levine, J. E. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.105.039800 · Cited by 165 · cited 1×
“The development of animal models to study PCOS has been an important research focus [11–14]; however, there is no consensus on the best experimental animal model to study PCOS.”
BackgroundShaw, N. D., Histed, S. N., Srouji, S. S., Yang, J., Lee, H., & Hall, J. E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2108 · Cited by 149 · cited 1×
“This was confirmed by multiple E2sensitive anatomical and molecular measures indicating that E2 was not significantly lowered: 1) both uterine weights and Pgr mRNA levels in several tissues were unchanged (both are reduced by lower E2 levels), and 2) FSH levels and Fsh mRNA expression were reduced rather than elevated…”
MethodGOODMAN, R. L., BITTMAN, E. L., FOSTER, D. L., & KARSCH, F. J. (1981) · Endocrinology · doi:10.1210/endo-109-5-1414 · Cited by 125
Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: Insight from animal models
Roland, A. V., & Moenter, S. M. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.04.002 · Cited by 57 · cited 1×
“It has been suggested that the absence of significant metabolic dysfunction or obesity in PNA mice signifies it as a lean PCOS model [73] and could be useful for representing the condition in some PCOS women who lack metabolic impairments [74].”
Background
Cited by
Control of puberty onset and fertility by gonadotropin-releasing hormone neurons
Herbison, A. E. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.70 · Cited by 515
Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome
Stener-Victorin, E., Padmanabhan, V., Walters, K. A., Campbell, R. E., Benrick, A., Giacobini, P., Dumesic, D. A., & Abbott, D. H. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa010 · Cited by 348
Self-citationThe gut microbiome is altered in a letrozole-induced mouse model of polycystic ovary syndrome
Kelley, S. T., Skarra, D. V., Rivera, A. J., & Thackray, V. G. (2016) · PLOS ONE · doi:10.1371/journal.pone.0146509 · Cited by 205
“Given that the effects of letrozole treatment on fertility appears to be reversible [35], future research should determine whether the effects of letrozole on the gut microbiome are similarly reversible or whether letrozole treatment results in permanent disruption of the gut microbiome.”
BackgroundInfluentialSelf-citationNew Perspectives on the Pathogenesis of PCOS: Neuroendocrine Origins
Walters, K. A., Gilchrist, R. B., Ledger, W. L., Teede, H. J., Handelsman, D. J., & Campbell, R. E. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.08.005 · Cited by 186
Androgens and ovarian function: translation from basic discovery research to clinical impact
Walters, K. A., Rodriguez Paris, V, Aflatounian, A., & Handelsman, D. J. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0096 · Cited by 104
Metadata
- Authors
- Kauffman, A. S., Thackray, V. G., Ryan, G. E., Tolson, K. P., Glidewell-Kenney, C. A., Semaan, S. J., Poling, M. C., Iwata, N., Breen, K. M., Duleba, A. J., Stener-Victorin, E., Shimasaki, S., Webster, N. J., & Mellon, P. L.
- Venue
- Biology of Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-01
- Volume
- 93
- Issue
- 3
- Pages
- 69-69
- ISSN
- 0006-3363 (ISSN-L)
- 1529-7268
- OpenAlex
- W1936533229
- Cited by
- 213
- References
- 30
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.